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IL-18, but Not IL-12, Induces Production of IFN-c in
the Immunosuppressive Environment of HPV16 E7
Transgenic Hyperplastic Skin
Christina Gosmann1, Ian H. Frazer1, Stephen R. Mattarollo1,2 and Antje Blumenthal1,2
IFN-g has a central role in the defense against infections and cancer. More recently, however, IFN-g has also been
reported to have immunosuppressive effects in models of autoimmune disease, melanoma, and premalignant
skin disease. Although IL-12 and IL-18 are critical inducers of IFN-g during infection, the mechanisms that induce
IFN-g in an immunosuppressive context are unknown. Previously, we identified a key role for IFN-g in mediating
the suppression of antigen-specific immune responses in a transgenic mouse model of human papillomavirus
(HPV)-associated epidermal hyperplasia, driven by the expression of the HPV16 E7 oncoprotein from a keratin 14
promoter (K14E7). We now demonstrate elevated production of IFN-g, IL-18, and IL-12 by K14E7 transgenic skin
compared with nontransgenic skin. IFN-g in K14E7 transgenic skin was produced predominantly by CD8þ and
CD4þ T cells, which were present in greater numbers in K14E7 transgenic skin. Production of IFN-g in K14E7 skin
required IL-18 but not IL-12. Our findings show that IL-18 contributes to inducing IFN-g in an immunosuppressive
cutaneous environment caused by viral oncogene–driven hyperplasia.
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INTRODUCTION
IFN-g is central to the defense against many pathogens, as well
as to the immune control of cancer (Dunn et al., 2006). During
innate immune responses, IFN-g is predominantly produced
by natural killer (NK) cells and natural killer T (NKT) cells,
whereas CD4þ Th1 and CD8þ cytotoxic T cells are the main
producers of IFN-g during adaptive responses (Schoenborn
and Wilson, 2007). More recently, IFN-g was reported to
suppress effective immune responses in models of experi-
mental autoimmune encephalomyelitis (Willenborg et al.,
1999; Minguela et al., 2007; Pastor et al., 2009). Further-
more, in a mouse model of UVB-induced melanoma, IFN-g-
producing macrophages were critical for tumor growth and
survival (Zaidi et al., 2011). These findings suggest dichoto-
mous functions of IFN-g in innate and adaptive immunity.
The inflammatory cytokines IL-18 and IL-12 are potent
inducers of IFN-g during infection, and are crucial for the
immune control of intracellular pathogens and viruses
(Okamura et al., 1995; Watford et al., 2004; Arend et al.,
2008). IL-18 is predominantly expressed by myeloid cells and
also by epithelial cells as a precursor protein that requires
protease-mediated cleavage, commonly by caspase-1, for
biological activity (Arend et al., 2008; Schroder and
Tschopp, 2010). IL-12, which consists of the p35 and p40
subunits, is primarily produced by activated myeloid cells. In
contrast to an infectious context, the mechanisms that induce
IFN-g in an immune-inhibitory and/or tumor-promoting
context are unknown.
Human papillomaviruses (HPVs) infect basal epithelial cells
of the skin or genital tract, and some HPV types can cause
cancer at these sites (zur Hausen, 2002). HPV proteins E6
and E7 inhibit differentiation and apoptosis of epithelial cells,
thus driving epithelial hyperplasia and transformation
(Moody and Laimins, 2010). Using a mouse expressing E7
driven by the keratin 14 (K14) promoter, a model of HPV16 E7
protein–induced epithelial hyperplasia (Herber et al., 1996),
we previously demonstrated that locally produced IFN-g
prevents effective host immune responses against K14E7
hyperplastic skin grafts (Mattarollo et al., 2010). These
findings revealed an immunosuppressive role for IFN-g in
K14E7 skin and make this model system suitable to investigate
the cytokine milieu that drives the expression of IFN-g in skin
expressing the HPV16 E7 oncogene.
Here, we report that the production of IFN-g, IL-12, and
IL-18 was higher in K14E7 transgenic skin compared with
nontransgenic skin. The majority of IFN-g-producing cells
were CD8þ and CD4þ T cells. Blocking IL-12 and IL-18
function showed that IFN-g production in K14E7 skin required
IL-18, but not IL-12. These observations provide insight into
the upstream signals that drive IFN-g production in an
immunosuppressive cutaneous environment.
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RESULTS
Elevated IFN-c production in K14E7 compared with wild-type
skin
Given the role for IFN-g in suppressing effective host immune
responses against K14E7 skin grafts (Mattarollo et al., 2010),
we first determined whether IFN-g production was different
between wild-type and K14E7 skin. To this end, we analyzed
IFN-g concentrations in supernatants from whole-skin
homogenate and from in vitro–cultured skin explants. IFN-g
concentrations in supernatants from wild-type skin homo-
genates and explants were very low or below the detection
limit, whereas IFN-g was readily detectable and significantly
elevated in supernatants from K14E7 skin (Figure 1a). Flow
cytometric analysis of unstimulated dermal and epidermal
cell suspensions further corroborated our findings on the
differential expression of IFN-g in wild-type and K14E7 skin.
Wild-type dermal and epidermal samples contained similar,
low numbers of IFN-g-producing cells (Figure 1b and c).
While the number of IFN-g-producing cells was comparable
in the dermis from K14E7 and wild-type mice, there were
more IFN-g-producing cells in K14E7 compared with wild-
type epidermis (9-fold increase compared with wild-type
epidermis) (Figure 1b and c). Further, stimulation of skin cell
suspensions with phorbol 12-myristate 13-acetate (PMA) and
ionomycin demonstrated that the numbers of cells with the
capacity to produce IFN-g were significantly elevated in the
dermis and epidermis of K14E7 mice compared with wild-type
mice (5- and 84-fold, respectively) (Figure 1b and c). More-
over, the majority of the cells with the capacity to produce
IFN-g in K14E7 skin were found in the epidermis (16-fold
higher numbers than in the dermis of K14E7 mice) (Figure 1b
and c). Together, these results demonstrate that IFN-g produc-
tion is increased in the skin of K14E7 animals compared with
wild-type animals, and that the majority of IFN-g-producing
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Figure 1. Elevated production of IFN-c in K14E7 skin compared with wild-type skin. (a) IFN-g concentrations in wild-type and K14E7 skin homogenates and
supernatants of skin explants (four mice per group). Data points indicate individual mice analyzed in at least two independent experiments. (b, c) Flow cytometric
analysis of cells isolated from dermis and epidermis of wild-type and K14E7 mice, unstimulated (unstim.) or stimulated with phorbol 12-myristate 13-acetate (PMA) and
ionomycin. (b) Total live cells gated for CD45.2þ IFN-gþ cells. Plots are representative of four independent experiments (two mice per strain per experiment).
(c) Numbers of CD45.2þ IFN-gþ cells in wild-type and K14E7 dermis and epidermis obtained from four independent experiments. Bars indicate means±SEM. (d) IL-6
and IL-1b concentrations in wild-type and K14E7 skin homogenates (four mice per group). ISO, isotype control; NS, not significant; WT, wild type.
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cells in K14E7 skin are located in the epidermis. In contrast to
IFN-g, IL-1b and IL-6 concentrations were significantly
reduced in K14E7 compared with wild-type skin homogenates
(Figure 1d), suggesting a specific modulation of the cytokine
environment rather than a general elevation of inflammatory
cytokine expression in K14E7 skin.
CD8 and CD4 T cells are the main producers of IFN-c in K14E7
skin
We next determined which cells are the major producers of
IFN-g in K14E7 skin. To identify IFN-g-producing cell popula-
tions in dermal and epidermal cell suspensions stimulated
with PMA and ionomycin, hematopoietic (CD45.2þ ) IFN-gþ
cells were gated for non-T cells (CD3 ) and T-cell (CD3þ )
subsets. The vast majority of IFN-g-producing cells in the
K14E7 epidermis were CD3þ T cells (94.8±1.2% (mean±
SEM)), with CD8þ T cells (56.2±6.4%) and, to a lesser
extent, CD4þ T cells (16.0±0.7%) as the predominant
IFN-g-producing subsets (Figure 2a and b). In contrast, few
IFN-g-producing cells were epidermal gd T cells (CD3hi
gdTCRhi) (1.3±0.6%), dermal gd T cells (CD3intgdTCRint)
(1.2±0.3%), and iNKT cells (0.8±0.1%). Findings in the
K14E7 dermis were similar, with 67.6±3.3% of IFN-g-produ-
cing cells being CD3þ T cells, 43.7±3.2% being CD8þ
T cells, 21.5±1.0% being CD4þ T cells, 2.5±1.0% being
iNKT cells, and 0.5±0.5% being dermal gd T cells (Figure 2a
and b). The mean fluorescence intensity of intracellular
IFN-g was similar among the cell subsets analyzed, indicating
that they produced comparable amounts of IFN-g (Figure 2c).
In summary, these findings show that the major producers
of IFN-g in K14E7 skin are CD8þ and, to a lesser extent,
CD4þ T cells.
Elevated IL-12 production in K14E7 skin is dispensable for IFN-c
production
IL-12 and IL-18 have a central role as inducers and enhancers
of IFN-g production (Arend et al., 2008; Watford et al., 2004).
It is currently unknown as to which of these mechanisms drive
the induction of IFN-g in the immunosuppressive environment
of K14E7 skin. We first investigated whether IL-12 is
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Figure 2. The majority of IFN-c-producing cells in K14E7 skin are CD8þ and CD4þ T cells. Flow cytometric analysis of cells isolated from the dermis and
epidermis of K14E7 mice, stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin. (a, b) Percentage of CD3þ , CD3þCD8þ , and CD3þCD4þ T
cells, iNKT cells, and gd T cells of CD45þ IFN-gþ cells. Plots are representative of four independent experiments (two mice per experiment), for which results are
summarized in b. (c) Mean fluorescence intensity of IFN-g-producing cell subsets from four independent experiments. Bars indicate means±SEM of four
independent experiments.
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differentially expressed in K14E7 compared with wild-type
skin. IL-12p40 mRNA levels were below the detection limit
of the assay in both wild-type and K14E7 skin samples
(data not shown). IL-12p70 and IL-12p40 concentrations
were, however, significantly elevated in supernatants of
in vitro–cultured K14E7 skin explants (Figure 3a). The obser-
vation that IL-12p40 protein but not mRNA was detectable in
K14E7 skin is likely due to the fact that RNA was extracted
from the tissue at a specific time point, containing the
IL-12p40 mRNA present in the tissue at that time. In contrast,
in tissue culture, IL-12p40 protein released by skin explants
accumulated in the supernatant over a period of 20 hours
before the protein concentration was determined. This circum-
stance likely facilitated the detection of IL-12p40 protein. To
investigate whether IL-12 was required for IFN-g production in
K14E7 skin, skin explants were cultured in the presence of a
neutralizing anti-IL-12p40 antibody. This did not lead to a
reduction of IFN-g secretion by the K14E7 skin explants
(Figure 3b), suggesting that IFN-g production in K14E7 skin
was not driven by IL-12. IL-12p40 is also a component of the
IL-23 heteromer, but a neutralizing anti-IL-23p19 antibody did
also not affect IFN-g secretion by K14E7 explants (Figure 3c).
Consistent with these findings, IFN-g concentrations in
the supernatants of skin explants from K14E7 transgenic
IL-12p40 / and control E7 transgenic IL-12p40þ / mice
were similar (Figure 3d), as was ear skin histology (data not
shown). Furthermore, K14E7 transgenic IL-12p40-deficient
skin grafts were accepted by immunocompetent wild-type
recipients, indicating that IL-12p40 was not required to locally
suppress host immune responses against the E7-expressing
graft (Gosmann et al., submitted). Together, these results
demonstrate that IL-12 is dispensable for IFN-g production in
K14E7 skin.
IL-18 production is elevated in K14E7 skin compared with
wild-type skin and acts upstream of IFN-c production in
K14E7 skin
We next investigated whether IL-18 was differentially
expressed in K14E7 compared with wild-type skin. IL-18
mRNA expression was significantly higher in K14E7 skin
(Figure 4a). Moreover, concentrations of secreted IL-18
protein in supernatants of K14E7 skin explants were signifi-
cantly elevated compared with wild-type skin explants, and
we confirmed the production of mature IL-18 in K14E7 skin
(Figure 4a). In line with this finding, mature caspase-1 was
also detectable in K14E7 skin (Figure 4b).
To investigate whether IL-18 was required for IFN-g
production in K14E7 skin, skin explants were cultured in the
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Figure 3. Elevated IL-12 production in K14E7 skin compared with wild-type skin is dispensable for IFN-c production. (a) IL-12p70 and IL-12/23p40
concentrations in supernatants of C57BL/6 and K14E7 skin explants following 20 hours of culture (n¼4 mice per group). Results are representative of at least
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presence of an IL-18-neutralizing antibody. This led to a
significant inhibition of IFN-g production by the explants
(Figure 4c). As IL-12 has been reported to enhance IL-18-
mediated IFN-g production (Yoshimoto et al., 1998), we
assessed whether simultaneous neutralization of IL-12 and
IL-18 inhibited IFN-g production to a greater extent compared
with inhibition of IL-18 alone. Skin explant cultures in the
presence of both anti-IL-18 and anti-IL-12 antibodies had
significantly reduced IFN-g concentrations in the culture
supernatant, but to no greater extent than IL-18 neutrali-
zation alone (Figure 4c; average inhibition 61% (anti-IL-18/
IL-12p40) compared with 72% (anti-IL-18)).
We aimed to assess the role for IL-18 in suppressing
effective immune responses against the HPV16 E7 antigen
by grafting E7 transgenic IL-18-deficient skin onto immuno-
competent nontransgenic recipients. However, breeding of
K14E7 with IL-18 / mice failed to produce E7 transgenic
IL-18 / progeny.
In summary, our findings suggest that IL-18, but not IL-12, is
required for the induction of IFN-g production in K14E7
skin, and that IL-12 does not enhance IL-18-induced IFN-g
production in K14E7 skin.
DISCUSSION
IFN-g is generally regarded as a proinflammatory cytokine.
In contrast, we previously reported that IFN-g promotes local
antigen-specific immunosuppression in E7-associated epi-
thelial hyperplasia (Mattarollo et al., 2010), and in a model
of UVB-induced melanoma IFN-g from macrophages
promoted melanocyte immune evasion in skin (Zaidi et al.,
2011). The aim of the present study was to identify the
mechanisms of IFN-g induction in E7-associated hyperplastic
skin, and to establish whether this would assist in
understanding the unexpected role of IFN-g in cutaneous
immunosuppression. Here, we report increased IFN-g, IL-12,
and IL-18 production in K14E7 transgenic hyperplastic skin
that was not associated with a more general inflammatory
response, as IL-1b and IL-6 production were in contrast
decreased (Figure 1d), and show that IL-18 but not IL-12
contributed to the production of IFN-g.
In the current study, CD8þ T cells and, to a lesser extent,
CD4þ T cells were the predominant producers of IFN-g in
K14E7 transgenic skin and were mostly found in the hyper-
plastic epidermis. Increased numbers of IFN-g-producing
cells were similarly detected in the hyperplastic epidermis of
atopic dermatitis lesions (Hijnen et al., 2013). T cells expres-
sing CCR6, a chemokine receptor involved in cell homing to
the epidermis (Mabuchi et al., 2013), are found in K14E7 skin
(Choyce et al., 2013), and the production of a cognate ligand
by hyperplastic skin may therefore similarly contribute to the
infiltrate of IFN-g-producing cells.
IL-18 could induce IFN-g production in K14E7 transgenic
hyperplastic skin by direct action on T cells or indirectly
through the activation of iNKT cells. iNKT cells, although they
constitute only a small percentage of the IFN-g-producing
cells in K14E7 transgenic skin, contribute to E7-specific local
immune suppression (Mattarollo et al., 2010), suggesting that
they might be a target of IL-18.
E7-reactive CD8þ T cells are eliminated in K14E7 trans-
genic mice (Frazer et al., 1998) because of E7 expression in
the thymus (Herber et al., 1996). Thus, IFN-g production by
CD8þ T cells in K14E7 skin is likely to occur in an antigen-
independent manner. Antigen-independent IFN-g production
by memory CD44hi CD8þ T cells in response to IL-12 and
IL-18 has been reported in bacterial infection (Berg et al.,
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Figure 4. IL-18 production is elevated and induces IFN-c production in K14E7
skin. (a) IL-18 mRNA expression in C57BL/6 and K14E7 skin (four mice per
group). IL-18 concentrations in supernatants of C57BL/6 and K14E7 skin
explants (20 hours; four mice per group). Means±SEM are indicated.
(a, b) Western blots showing (a) pro-IL-18 (24 kDa), mature IL-18 (18 kDa)
(n¼ 3 mice), (b) pro-caspase-1 (45 kDa), and mature caspase-1 (10 kDa)
(n¼ 2 mice) in K14E7 skin lysates. b-Actin served as a loading control.
Results are representative of at least two independent experiments.
(c) IFN-g concentrations in supernatants of K14E7 skin explants cultured
with 10mg ml1 isotype or anti-IL-18 and/or anti-IL-12/23p40 antibodies for
40 hours. Data are paired observations for the same mouse, analyzed in
two independent experiments (8–9 mice per treatment). ISO, isotype control;
WT, wild type.
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2002; Berg et al., 2003; Kambayashi et al., 2003) and in
cytokine-stimulated human peripheral blood CD4þ T cells
(Munk et al., 2011). However, IFN-g production in K14E7 skin
does not require IL-12, suggesting that different mechanisms
may induce IFN-g in infections and in E7-associated skin
hyperplasia.
Although IL-18 and IL-12 synergize in inducing IFN-g
production during infection (Yoshimoto et al., 1997; Takeda
et al., 1998; Berg et al., 2002; Kambayashi et al., 2003), we
unexpectedly found that, in E7-induced skin hyperplasia, IL-
18 but not IL-12 contributed to IFN-g production. In a mouse
model of hyperplastic epithelium associated with atopic
dermatitis, overexpression of IL-18 in serum and IL-12 in
skin-draining lymph nodes was also observed, and IL-18 was
required for the induction of IFN-g-producing Th1 cells in
skin-draining lymph nodes, but the contribution of IL-12 was
not assessed (Terada et al., 2006). Molecular mechanisms
underlying the synergy of IL-18 and IL-12 in inducing IFN-g
expression include IL-12-mediated upregulation of IL-18
receptor expression (Yoshimoto et al., 1998) and enhanced
binding of IL-18-induced AP-1 to the IFN-g promoter via a
STAT4-mediated mechanism downstream of IL-12 signaling
(Nakahira et al., 2002). Although the detailed molecular
mechanisms of IFN-g induction in K14E7 transgenic skin
remain to be elucidated, IL-12 might not synergize with IL-
18 for IFN-g production in E7-induced epithelial hyperplasia
because IL-18 receptor expression is not induced, IL-12
receptor expression is downregulated, or because alternative
mechanisms of STAT4 activation, as seen in response to some
infections (Buxbaum et al., 2002; Freudenberg et al., 2002),
render a requirement for IL-12 redundant. IL-23 can also
induce IFN-g production in T cells (Oppmann et al., 2000)
and NKT cells (van de Wetering et al., 2009). However,
blocking IL-23p19 in K14E7 transgenic skin explant cultures
did not significantly alter IFN-g production by K14E7 skin
explants, ruling out a major contribution of IL-23.
This study demonstrates that IL-18 drives IFN-g production
in hyperplastic skin, contributing to an immunosuppressive
environment. In line with this finding, an association between
IL-18 promoter polymorphisms and the risk of developing
HPV-associated cervical cancer has been reported (Sobti et al.,
2008). IL-18 shows antitumor activity in several preclinical
animal models, but it was not effective in patients with meta-
static melanoma (Tarhini et al., 2009; Srivastava et al., 2010).
Our findings suggest that, for skin-associated malignancy,
local blockade of IL-18 rather than systemic administration
could facilitate effective antitumor immune responses.
MATERIALS AND METHODS
Mice
C57BL/6J (wild type) mice and HPV16 E7 transgenic C57BL/6J mice
expressing the E7 oncoprotein under control of the K14 promoter
(K14E7; Herber et al., 1996) were from the Animal Resources Centre
(Perth, WA, Australia). IL-12p40 / (Magram et al., 1996) and
IL-18 / (Takeda et al., 1998) mice were obtained from Camile
Farah (The University of Queensland Centre for Clinical Research,
Brisbane, QLD, Australia) and Ben Croker (The Walter and Eliza Hall
Institute of Medical Research, Melbourne, VIC, Australia),
respectively. All mice were maintained under specific pathogen-free
conditions. To generate K14E7 mice deficient in IL-12p40 or IL-18,
hemizygous K14E7 mice were crossed and the E7-expressing progeny
backcrossed with homozygous IL-12p40 / and IL-18 / mice.
Mice were sex- and age-matched for all experiments. Animal
procedures were approved by the University of Queensland Animal
Ethics Committee (AEC# 290/10/NHMRC/NIH).
Preparation of skin homogenate
Mouse ears were snap frozen and homogenized on ice in phosphate-
buffered saline with protease inhibitor (cOmplete ULTRA Mini,
Roche, Basel, Switzerland) using a T 10 basic ULTRA-TURRAX
homogenizer (IKA, Staufen im Breisgau, Germany). Homogenates
were centrifuged (18,000 r.c.f., 10 minutes, 4 1C) and the supernatant
was collected. Total protein concentration was determined using the
BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA).
Skin explant culture
Mouse ears were split and placed dermis-side down on DMEM with
10% fetal bovine serum, penicillin/streptomycin/glutamine (1 mM),
sodium pyruvate (1 mM) (Gibco, Mulgrave, VIC, Australia), and HEPES
(10 mM) (Invitrogen, Carlsbad, CA) in 24-well plates. To remove
cytokines released as a result of tissue preparation, the medium was
exchanged after 1 hour and another 2 hours of culture (37 1C, 5%
CO2). Medium changes reduced the lactate dehydrogenase activity
(CytoTox 96 NonRadioactive Cytotoxicity Assay; Promega, Fitchburg,
WI) in the supernatant to medium control levels 2 hours after the last
medium exchange (data not shown). Supernatants were collected
20 hours after the last medium replacement for cytokine analysis by
ELISA, and low lactate dehydrogenase activity in the supernatants was
confirmed (data not shown).
For cytokine neutralization in skin explant cultures, culture med-
ium was supplemented with monoclonal antibodies against IL-18
(93-10C) (MBL, Woburn, MA) and IL-12/23p40 (C17.8) (eBioscience,
San Diego, CA) or matched isotype control antibodies from the
same company. Anti-IL-23p19-neutralizing and matched isotype
control antibodies were provided by Lilly Research Laboratories
(Indianapolis, IN). The dorsal (or ventral) half from one ear was
treated with neutralizing antibody and compared with the dorsal
(or ventral) half from the other ear of the same mouse, treated with
isotype control antibody. Supernatants were replaced after 20 hours
with antibody-supplemented medium and collected after another
20 hours for analysis by ELISA.
Cytokine ELISA
ELISA (mouse IFN-g, IL-23 (eBioscience); total IL-18 (MBL); IL-12p70,
IL-12/23p40, IL-6, total IL-1b (BD Biosciences, San Jose, CA)) was
performed according to the manufacturers’ instructions. Samples
undetectable within the assay range were plotted as the detection
limit. Cytokine concentrations in supernatants of skin explant cultures
and skin homogenates were normalized to tissue weight and total
protein concentrations, respectively.
Isolation and stimulation of skin cells
Mouse ears were split into halves and incubated dermis-side down in
2 mg ml 1 dispase in phosphate-buffered saline (Roche) for 1 hour at
37 1C. To obtain sufficient cell numbers for analysis, ears from two
mice per strain were combined for processing. Dermis and epidermis
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were separated and incubated in phosphate-buffered saline contain-
ing 0.3 mg ml 1 collagenase and 5mg ml 1 of DNase (Roche)
(dermis), or 0.25% trypsin, 0.1% EDTA, and 5mg ml 1 DNase
(epidermis), for 30 minutes at 37 1C. The resulting tissue fragments
were vigorously pipetted and the cell suspension was passed through
a 40-mm cell strainer (BD Biosciences).
Up to 1 106 of total cells per milliliter were stimulated with
1mg ml 1 PMA and 0.5mg ml 1 ionomycin (Calbiochem/EMD4Bio-
sciences, San Diego, CA) in complete medium (supplemented as
detailed above) for 4 hours at 37 1C. After 30 minutes, monensin
(BioLegend, San Diego, CA) and GolgiPlug (BD Biosciences) were
added to the cultures to inhibit cytokine release from the Golgi/
endoplasmic reticulum complex for intracellular cytokine staining.
Flow cytometry
Monoclonal antibodies against mouse CD45.2 (104), CD3e (145-
2C11), TCRgd (GL3), IFN-g (XMG1.2), and corresponding isotype
controls were from BD Biosciences. Anti-CD8a (53-6.7) and CD4
(RM4-5) antibodies were from eBioscience. a-GalCer-loaded CD1d
tetramer for the detection of invariant NKT cells was kindly provided
by Dale Godfrey (University of Melbourne, VIC, Australia). Cell
suspensions were incubated with Fc block (BD Biosciences) for
15 minutes, followed by Live/Dead Fixable Aqua Dead Cell Stain
(Invitrogen) and antibodies against cell surface markers for 20 min-
utes. For intracellular cytokine staining, cells were fixed and permea-
bilized (BD Biosciences Cytofix/Cytoperm kit). Antibodies against
cytokines and matched isotype control antibodies were added for
30 minutes. All steps were performed at 4 1C. Flow Count Fluoro-
spheres (Beckman Coulter, Brea, CA) were used for the calculation of
cell numbers. The samples were acquired on a Gallios (Beckman
Coulter) flow cytometer. Data were analyzed using the Kaluza
software 1.2 (Beckman Coulter). Doublets and dead cells were
excluded from analysis.
Quantitative real-time PCR
For RNA extraction, mouse ears were homogenized in TRIzol
(Invitrogen). Total RNA was purified using the RNeasy Mini Kit
(Qiagen, Venlo, Netherlands) and reversely transcribed using Oligo
d(T) (Applied Biosystems, Foster City, CA). Primers for SYBR Green
quantitative real-time PCR were purchased from Integrated DNA
Technologies (Coralville, IA) and were designed using the Primer-
Quest PCR design tool (Integrated DNA Technologies). Primer
sequences: mHPRT FW: 50-CCCCAAAATGGTTAAGGTTGC-30;
mHPRT RV: 50-AACAAAGTCTGGCCTGTATCC-30. Predesigned Taq-
Man gene expression assays (Integrated DNA Technologies) were
used for mouse IL-12 and IL-18. Quantitative real-time PCR was
performed using a 7900HT Fast Real-Time PCR System (Applied
Biosystems). Data were analyzed using the SDS Software 2.4 (Applied
Biosystems). mRNA expression relative to the housekeeping gene
hypoxanthine-guanine phosphoribosyl-transferase (HPRT) was calcu-
lated as 2^(Ct (HPRT)Ct (gene of interest)).
Western blot
Mouse ears were snap frozen and homogenized on ice in RIPA buffer
(1% Triton-X, 20 mM Tris pH 7.5, 150 mM NaCl, protease inhibitor
(Roche), in Milli-Q H2O) using a T 10 basic ULTRA-TURRAX
homogenizer. Homogenates were centrifuged (18000 r.c.f., 10 min-
utes), and the supernatant was collected and filtered through a 70-mm
cell strainer (BD Biosciences) to remove aggregates (4 1C). Total
protein concentration was determined as above.
At least 50mg of denatured skin lysate per sample and Rainbow
Molecular Weight Markers (GE Healthcare, Chalfont St Giles, UK)
were separated on 15% (IL-18) or 12% (caspase-1) polyacrylamide
gels and transferred onto 0.45-mm polyvinylidene fluoride membranes
(EMD Millipore, Billerica, MA). Blots were blocked with 5% skim milk
in Tris-buffered saline/0.1% Tween20 (1 hour, RT) and incubated with
primary antibodies against mouse IL-18 (39-3F; MBL), caspase-1 p10
(sc-514; Santa Cruz Biotechnology, Dallas, TX), or b-actin (AC-15;
Sigma-Aldrich, St Louis, MO), followed by horseradish peroxidase-
conjugated secondary antibody. Blots were developed using Super-
Signal West Dura Chemiluminescent Substrate (Thermo Fisher Scien-
tific). Images were acquired with ChemiDoc (Bio-Rad, Hercules, CA).
Statistics
Statistical analysis was performed using Prism (Graphpad Software,
La Jolla, CA). Paired Student’s t-test was used to compare data from
skin explant cultures treated with specific and isotype control
antibodies. All other groups were compared by unpaired Student’s
t-test. Differences were considered significant at Po0.05 and
are indicated as *Po0.05, **Po0.01, and ***Po0.001. NS, not
significant.
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